RASA1, a negative regulator of the Ras-mitogen-activated protein kinase (MAPK) signaling pathway, is essential for the development and maintenance of lymphatic vessel (LV) valves. However, whether RASA1 is required for the development and maintenance of lymphovenous valves (LVV) and venous valves (VV) is unknown. In this study we show that induced endothelial cell (EC)-specific disruption of Rasa1 in mid-gestation mouse embryos did not affect initial specification of LVV or central VV but did affect their continued development. Similarly, switch to expression of a catalytically inactive form of RASA1 resulted in impaired LVV and VV development. Blocked development of LVV in RASA1-deficient embryos was associated with accumulation of the basement membrane protein, collagen IV, in LVV-forming EC and could be partially or completely rescued by MAPK inhibitors and drugs that promote collagen IV folding. Disruption of Rasa1 in adult mice resulted in venous hypertension and impaired VV function that was associated with loss of EC from VV leaflets. In conclusion, RASA1 functions as a negative regulator of Ras signaling in EC that is necessary for EC export of collagen IV, thus permitting the development of LVV and the development and maintenance of VV.
Introduction
The Ras signaling pathway is a ubiquitous intracellular signaling pathway that is triggered by different growth factor receptors (GFR) in numerous cell types. 1, 2 Ras is a small GTP-binding protein, tethered to the inner leaflet of the cell membrane, which switches between inactive GDP-bound and active GTP-bound states. GFR activate Ras through recruitment to membranes of one or more Ras guanine nucleotide exchange factors (RasGEFs) that eject GDP from the Ras guanine nucleotide-binding pocket, thus permitting Ras to bind GTP. 3 Activated GTP-bound Ras induces different downstream signaling cascades including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling cascades that couple GFR and Ras to cellular responses. 4, 5 Inactivation of Ras is mediated by Ras GTPase-activating proteins (RasGAPs) that increase the ability of Ras to hydrolyze bound GTP to GDP by several orders of magnitude. 6 There are ten different members of the RasGAP family that each comprise of a catalytically active GAP domain together with one or more modular binding domains. 6 Most members of the RasGAP family are expressed broadly in different tissues and cell types. Nonetheless, one RasGAP family member, p120 RasGAP (also known as RASA1), has emerged as a critical regulator of blood vessel (BV) and lymphatic vessel (LV) systems in both humans and mice. In humans, germline inactivating mutations of the RASA1 gene cause the autosomal dominant blood vascular disorder, capillary malformation-arteriovenous malformation (CM-AVM). [7] [8] [9] Recent evidence indicates that the development of BV lesions in CM-AVM is dependent upon the acquisition of somatic inactivating second hit mutations in the intact RASA1 allele in endothelial cells (EC) or their progenitors during development. 10, 11 This is consistent with the variable phenotype and location of BV lesions in CM-AVM patients. In addition, LV abnormalities, including lymphedema, chylous ascites, chylothorax and LV hyperplasia have also been observed in some CM-AVM patients. 8, 9, [11] [12] [13] [14] Non-conditional disruption of the Rasa1 gene in mice results in mid-gestation lethality (E10.5) as a consequence of abnormal vasculogenesis and developmental angiogenesis in which primitive vascular plexuses are remodeled into hierarchical arterial-capillaryvenous networks. 15, 16 In addition, disruption of Rasa1 in neonatal and adult mice results in impaired retinal angiogenesis and pathological angiogenesis respectively. [17] [18] [19] We recently demonstrated that in the absence of RASA1, endothelial cells (EC) are unable to export the extracellular matrix protein, collagen IV, which is major constituent of vascular basement membranes (BM). This inability to export collagen IV, accounts for the impaired developmental, neonatal and pathological angiogenic responses in the absence of RASA1. Concerning the LV system, induced disruption of Rasa1 in adult mice results in LV leakage in the form of chylous ascites and chylothorax. 18 This can be explained on the basis that RASA1 is required for the maintenance of intra-luminal valves in collecting LV that normally prevent backflow of lymph fluid. 20 Upon Rasa1 disruption, lymphatic EC (LEC) are lost from LV valve leaflets at the rate of approximately one LEC per leaflet per week until a threshold point is reached where the valve is unable to prevent fluid backflow and is unable to function. 20 RASA1 is also necessary for the development of LV valves in late gestation. Disruption of Rasa1 just prior to LV valvulogenesis at E15.5 does not impact upon initial LV valve specification characterized by increased expression of the PROX1 transcription factor in valve-forming LEC. 20, 21 However, all PROX1 hi valve-forming LEC undergo apoptosis shortly thereafter and valve development ceases. 20 Lymph fluid is returned to the blood circulation via LV that connect with the blood vasculature at the junction of the internal jugular vein (IJV), external jugular vein (EJV) and subclavian veins (SCV) with the superior vena cava (SVC). 22, 23 Lymphovenous valves (LVV) guard the four points of connection of these LV with the blood vasculature (two points of connection on either side of the animal) and, thereby, prevent backflow of blood into LV. 22, 23 LVV first form at E12 at the point of contact of lymphatic sacs (LS) with the blood vasculature. LVV specification is marked by the up-regulation of PROX1 by both LEC on the lymphatic side and LVV-forming EC on the venous side of the nascent valve structure. 22, 23 LVV development then proceeds through the successive stages of delamination, aggregation and maturation as LVV leaflets form and extend into the vein lumen; a process that is considered complete by E16.5. 22 Mature LVV leaflets comprise of two different types of EC attached to a central extracellular matrix (ECM) core. 22 EC on the lymphatic and venous sides of leaflets continue to express high levels of PROX1. LEC on the lymphatic side of leaflets express high levels of vascular endothelial growth factor receptor 3 (VEGFR3), the receptor for VEGF-C. In contrast, EC on the venous side of LVV leaflets express low levels of VEGFR3 while the rest of the venous endothelial cells are VEGFR3 negative. Since RASA1 is necessary for the development of LV valves, it is important to determine if it performs a similar function in the development of LVV and, if so, at which stage.
VV prevent backflow of blood and are required for unidirectional flow of blood in veins 24 . Dysfunction of VV has serious consequences that include chronic venous insufficiency, venous hypertension and deep vein thrombosis. 25, 26 Development of VV in central veins, such as the IJV, EJV and SCV, is initiated at E14.5 and is completed by E16.5. 22, 27 In contrast, VV in peripheral veins, such as the saphenous vein, develop postnatally. 27, 28 VV specification, like LV valve and LVV specification, is marked by increased expression of PROX1 in valve-forming EC. 22, 24 Mature VV are structurally similar to LV valves in that leaflets of both type of valve comprise of a single type of EC attached to a central ECM core. VV and LV valve leaflet EC both continue to express high levels of PROX1 and share several other molecular characteristics including high level expression of the FOXC2 transcription factor and alpha-9 integrin. 22, 24 Given the similarity between VV and LV valves, investigation as to whether or not RASA1 is necessary for the development and maintenance of VV is also important.
In the current studies, we used different mouse models of RASA1 deficiency to demonstrate a role for RASA1 in the development and maintenance of LVV and VV.
Furthermore, we established that RASA1 is necessary for the export of collagen IV from valve-forming EC, which explains its role in valve development. Studies are of potential relevance to an understanding of the pathogenesis of CM-AVM and are of additional significance to other cardiovascular diseases.
Results

RASA1 is not required for the specification of LVV and central VV. Specification of
LVV occurs at E12 and is marked by increased expression of PROX1 in LEC and LVVforming EC at the points that LS make contact with BV in the region of the junction of the IJV, EJV, SCV and SVC. 22, 23 Therefore, to examine if RASA1 plays a role in LVV specification, we administered TM to pregnant Rasa1 fl/fl mice carrying Rasa1 fl/fl and Rasa1 fl/fl Cdh5 ert2cre embryos at E10.5 and analyzed embryos at E12.5. The Cdh5 promoter drives expression of the ert2cre transgene within EC specifically. 29 As assessed by staining of frontal tissue sections for PROX1, VEGFR3 and CD31, induced disruption of Rasa1 at E10.5 in Rasa1 fl/fl Cdh5 ert2cre embryos did not affect LVV specification (Figure 1 A) .
We also examined if RASA1 was required for the specification of central VV.
Specification of the VV that guard the points of entry of the IJV, EJV and SCV into the SVC occurs at E14.5. 22, 27 Similar to LVV and LV valve specification, VV specification is characterized by increased expression of PROX1 and VEGFR3 in VV-forming EC. Therefore, to examine if RASA1 is required for VV specification, we administered TM to pregnant Rasa1 fl/fl mice carrying Rasa1 fl/fl and Rasa1 fl/fl Cdh5 ert2cre embryos at E12.5 and analyzed embryos at E14.5 for PROX1 and VEGFR3 expression at the respective venous junctions (Figure 1 B ). Loss of RASA1 in EC at E12.5 did not affect VV specification. Therefore, RASA1 is dispensable for the specification of VV as well as LVV.
RASA1 is required for the continued development of LVV and central VV.
Development of LVV and central VV continues through E16.5 as valve leaflets are extended into the vessel lumen. 22, 23 To determine if RASA1 is required for continued LVV and central VV development, we administered TM to Rasa1 fl/fl and Rasa1 fl/fl Cdh5 ert2cre embryos at E12.5 and analyzed embryos at E16.5. LVV and VV structure was analyzed by immunostaining of tissue sections and by SEM ( Figure 2 A and B ). In 
Impaired development of LVV and central VV in embryos that express RASA1
R780Q alone. Some studies have indicated that RASA1 can participate in intracellular signaling pathways independent of its ability to promote Ras hydrolysis of GTP. 6 Therefore, we examined if the function of RASA1 in LVV and central VV development was dependent upon its catalytic GAP activity. For this purpose, we used a Rasa1 R780Q allele that we reported previously. 20 R780 of RASA1 is the "arginine finger" of the GAP domain that is essential for GAP activity. 6, 16 Mutation of this arginine to glutamine in R780Q thus abrogates GAP activity, although is predicted to leave all other putative RASA1 functions intact. Since Rasa1 R780Q/R780Q embryos die at E10.5 of gestation 16 
Loss of RASA1 results in accumulation of collagen IV in EC of LVV.
We recently determined that global or EC-specific disruption of Rasa1 at E13.5 results in the apoptotic death of all dermal EC at E18.5 or E19.5 respectively. 19 In the absence of RASA1, the vascular BM protein, collagen IV, is retained within the endoplasmic reticulum (ER) of EC and smooth muscle cells. As a result of the reduced amounts of collagen IV in BM, EC fail to attach properly to BM and undergo apoptotic death. Based upon these findings, we asked if induced loss of RASA1 at E12.5 results in intracellular accumulation of collagen IV in EC of LVV. An inability of LVV EC to export collagen IV for deposition in the ECM core of developing LVV leaflets would provide an explanation for failed LVV development. In embryos administered TM at E12.5, developing LVV are present at E14.5 (Figure 1 B ) but absent at E16.5 ( Figure 2 ). Therefore, we examined E15.5 embryos for any evidence of EC collagen IV accumulation in LVV EC. At E15.5, LVV in TM-treated (at E12.5) Rasa1 fl/fl Cdh5 ert2cre embryos were frequently abnormal and separation of the two EC layers was often observed (Supplemental Figure 1 ). We examined collagen IV accumulation in embryos that additionally carried a Prox1-eGFP transgene. 30 
Rescue of LVV development by a chemical chaperone that promotes folding of collagen IV.
Collagen IV becomes trapped in the ER of RASA1-deficient EC as a consequence of impaired collagen IV folding. Accordingly, 4PBA, a chemical chaperone that promotes folding of collagen IV in the ER, 31, 32 rescues EC export of collagen IV and EC apoptosis. 19 Therefore, we examined if 4PBA could rescue LVV and central VV development in the absence of RASA1. 4PBA was administered along with TM to 
Rescue of LVV development by an inhibitor of collagen IV modifying enzymes.
Folding of two alpha 1 and one alpha 2 collagen IV monomers into a triple helical protomer conformation in the ER is a highly regulated process that requires multiple post-translational modifications of monomers mediated by protein disulphide isomerases (PDIs), protein peptidyl isomerases (PPIs), proline-3 and proline-4 hydroxylases (P3H1-3 and P4HA1-3 respectively) and lysine hydroxylases and glycosylases (procollagenlysine, 2-oxoglutarate 5-dioxygenases -PLODs 1-3). [33] [34] [35] [36] Under-or over-posttranslational modification of collagen IV monomers can affect folding of monomers into the triple helical conformation. Proteomic analyses of induced RASA1-deficient embryonic BEC established that of the P3H, P4HA and PLOD enzymes that could be detected in these cells (7 out of a total of 9), all were increased in abundance compared to control RASA1-sufficient BEC. 19 P3Hs, P4HAs and PLODs all belong to the same family of enzymes known as 2-oxoglutarate (2OG)-dependent oxygenases (2OG-DO) and, consequently, can be collectively inhibited by drugs such as 2,4 pyridinedicarboxylic acid (2,4 PDCA). 37, 38 Consistent with the notion that increased abundance of 2OG-DO in embryonic RASA1-deficient BEC is responsible for the impaired folding and export of collagen IV, 2, 4 PDCA rescued collagen IV retention and BEC apoptosis in induced global RASA1-deficient embryos. 19 Based on these findings, we asked if 2,4 PDCA could also rescue LVV and VV development in the absence of RASA1. As in previous drug rescue experiments, 2,4 PDCA was administered with TM to E12.5 Rasa1 fl/fl and 
RASA1 is necessary for the maintenance of central venous valves in adults.
To determine if RASA1 is necessary for the maintenance of central VV in adults, we administered TM to adult littermate Rasa1 fl/fl and Rasa1 fl/fl Ub ert2cre mice and examined VV function 3 months later. As a first approach, we examined central venous pressure that would be expected to be elevated in mice as a consequence of impaired VV function. 39 Central venous pressure was monitored by telemetry throughout the 24-hour daily cycle for 6 days for each examined mouse (Figure 8 A) . In these experiments Rasa1 is disrupted prior to E15.5 and results in their apoptotic death, either as a result of anoikis (detachment from the substratum) or induction of an unfolded protein response. 19 We propose that impaired export of collagen IV from EC of induced RASA1-deficient LVV, VV and LV valves is responsible for failed valve development. An inability of RASA1-deficient valve forming EC to export collagen IV for deposition in the developing ECM core of valves would be expected to result in EC detachment from the valve and/or induction of a UPR. Blocked export of collagen IV from RASA1-deficient embryonic EC and hemorrhage can be rescued by 4PBA that promotes folding of collagen IV in the ER. Similarly, in the current study, 4PBA largely rescued the impasse in LVV development and partially rescued the block in VV development in the absence of RASA1. These findings support the concept that collagen IV is retained within EC of developing RASA1-deficient LVV and VV because it is improperly folded. Our earlier proteomic studies of RASA1-deficient BEC identified increases in the abundance of all detectable collagen IV-modifying 2OG-DO enzymes in these cells. Evidence that this increase is responsible for collagen IV misfolding and retention in BEC was provided by the finding that drugs such as ethyl-3,4-dihydroxybenzoic acid (EDHB) and 2,4 PDCA, which broadly inhibit this class of enzymes, rescued collagen IV export from BEC and prevented hemorrhage. Similarly, as shown here, 2,4 PDCA rescued both LVV and VV development in the absence of RASA1. This is consistent with a model in which an increased abundance of 2OG-DO in EC of LVV and VV results in collagen IV retention in the ER, that in turn is responsible for blocked development of these valves in the absence of RASA1.
Induced loss of RASA1 in adult mice has not previously been reported to result in any spontaneous BV phenotypes. 18 This can be explained on the grounds that deposition of collagen IV in BM primarily occurs during developmental angiogenesis. Collagen IV is an inherently stable molecule, thus obviating a requirement for EC to continue to engage in high rate collagen IV synthesis in postnatal life. 40 A requirement of RASA1 for VV maintenance in adults represents an exception to this and parallels a requirement of RASA1 in the maintenance of LV valves in adults. 20 Dysfunction of LV valves in induced RASA1-deficient mice can be explained by gradual loss of LEC from LV valve leaflets resulting in leaflet shortening below a threshold level necessary prevent to fluid backflow when closed leaflets overlap. Similarly, we show here that VV dysfunction is associated with reduced cellularity of VV leaflets. EC in LV valves and VV would be subject to higher shear stress forces than EC in LV and BV walls to the extent that continued high rate synthesis of collagen IV may be necessary for these cells to remain attached to the valve leaflet. 41, 42 Indeed, it is established that EC synthesize higher amounts of collagen IV when subject to shear stress in vitro. 43 
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Methods
Mice. Rasa1 fl/fl and Rasa1 fl/R780Q mice with and without Ub ert2cre transgenes have been described. [16] [17] [18] 20 Cdh5 ert2cre mice were obtained from Cancer Research UK. 29 Immunohistochemistry on sections was performed as described. 22 Fixed embryos were embedded in OCT solution (Sakura, Tokyo, Japan) and 12 μm thick cryosections were prepared in the frontal orientation using a cryotome (Thermo Fisher Scientific, Model: HM525 NX). Primary antibodies used were: goat anti-VEGFR3 (R&D Systems), rabbit anti-PROX1 (AngioBio), rat anti-CD31 (BD Pharmingen), goat anti-collagen IV (1340-01, Southern Biotech), rabbit anti-pERK (D13.14.4E, Cell Signaling Technology).
Secondary antibodies were fluorochrome-labeled species specific anti-Igs. The antibodies were diluted in blocking buffer (PBS+ 0.1% Triton X-100 +0.1% BSA) and immunohistochemistry was performed using standard protocols. After mounting, the sections were visualized with Eclipse 80i microscope (Nikon, Tokyo, Japan) equipped with Zyla sCMOS camera (Andor Technology, Belfast, UK) and analyzed using NIS-Elements BR software (Nikon, Tokyo, Japan). Several consecutive sections were analyzed to determine the presence or absence of LVVs and VVs.
SEM was performed according to our previous protocol. 22, 44 Briefly, 500 µm sections were prepared using vibratome (Leica, Buffalo Grove, IL, USA). Sections were fixed in pressure. Development of spontaneous tone confirmed vessel viability but the venous valve tests described below were performed after perfusion of the segment with Ca 2+ -free Krebs (Krebs with 3 mM EDTA replacing CaCl 2 ·2H 2 O) for at least 20 minutes to eliminate spontaneous tone. The vessel image was digitized using a fire-wire camera (model A641FM; Basler) and inner diameter was continuously tracked using a custom computer algorithm. 46 All valve tests were recorded as AVI files, with embedded pressure and diameter data, for later replay and valve tracking, as needed.
Valve back-leak assays. To conduct tests of valve function, the pressure control for each cannulation pipette was switched from the reservoirs to a two-channel pump controller (Cardiovascular Research Institute, Texas A&M University) driven through a D-A interface by a LabVIEW program (National Instruments) running under Windows 7. A servo-nulling micropipette with tip diameter ~3 µm was inserted through the vessel wall on the upstream side of the valve to measure the local pressure (Psn) at that site. 46 
